Share
Dr. José Iglesias
Agenus Inc., a leader in immuno-oncology innovation, has appointed José Iglesias, M.D., as its new Chief Medical Affairs Officer.
In this role, Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL), as the combination advances through Phase 3 clinical evaluation and expands availability through early-access programs worldwide, including France’s Autorisation d’Accès Compassionnel (AAC).
BOT is an Fc-enhanced multifunctional CTLA-4 antibody, while BAL is a PD-1 antibody. Together, the BOT/BAL combination is being investigated for the treatment of microsatellite-stable colorectal cancer (MSS CRC), a patient population with significant unmet need and historically limited benefit from immunotherapy.
Dr. Iglesias brings more than 30 years of global oncology and immuno-oncology drug development experience. Earlier in his career at Abraxis BioScience and Celgene, he played a pivotal role in the late-stage development and lifecycle management of Abraxane, supporting its adoption in pancreatic, lung, and metastatic breast cancers. More recently, he held senior medical leadership positions at Bionomics, Biothera, and Apobiologix, overseeing global oncology programs across biologics, small molecules, and immunotherapies.
At Agenus, Dr. Iglesias will oversee medical evidence generation, scientific communications, and engagement with clinicians, investigators, and health authorities. He will also guide the appropriate use of BOT/BAL within regulatory and early-access frameworks, including France’s AAC program, with a strong emphasis on real-world evidence collection.
Dr. Iglesias has authored over 70 peer-reviewed publications and is an active member of ASCO, AACR, and ESMO. He earned his medical degree in Uruguay and completed advanced fellowships in Canada, Israel, and the United States before beginning his career in oncology practice.
